ArticleVeterinary medicine and science2026
Angiopoietin-1, Angiopoietin-2 and Vascular Endothelial Growth Factor Levels in Canine Leishmaniosis.
Article in Veterinary medicine and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCanine leishmaniosis (CanL) is a zoonotic vector-borne disease and is primarily associated with systemic inflammation, endothelial dysfunction and immune dysregulation. Although angiopoietins (Ang) and vascular endothelial growth factor (VEGF) are key regulators of vascular homeostasis, their roles in CanL have remained unclear.
objectivesThe present study aimed to evaluate Ang-1, Ang-2 and VEGF levels in CanL, in relation to disease severity and inflammatory markers.
methodsThe study included 74 dogs (52 with CanL and 22 healthy controls). The dogs with CanL were categorized into four groups based on disease severity. Plasma levels of Ang-1, Ang-2 and VEGF were measured with commercial ELISA kits. The correlations of these parameters with disease progression and inflammatory markers, such as C-reactive protein (CRP) and ferritin, were statistically analysed.
resultsAng-1 and VEGF levels were significantly elevated in advanced stages of CanL, suggesting a compensatory response to vascular damage and chronic inflammation. Ang-2 levels increased in both early and late stages, indicating endothelial destabilization and inflammatory progression. VEGF correlated with disease severity and aligned with enhanced vascular permeability. CRP and ferritin levels increased with disease severity and reflected systemic inflammation.
conclusionsThis study highlights the potential role of VEGF, Ang-1 and Ang-2 in CanL progression. High levels of VEGF and Ang-2 suggest enhanced vascular permeability and inflammation, whereas elevated Ang-1 may indicate a compensatory response. Overall, these parameters have the potential to be used as biomarkers for monitoring disease progression and as targets for therapy. Additional studies with larger cohorts and advanced imaging techniques are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.